Akiko Miyagi-Maeshima

14PUBLICATIONS
41CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedMedical infection agents (incl. prions)Predictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jun 16, 2026
Association between CD79B expression and polatuzumab vedotin efficacy, and therapy-induced changes in CD79B expression in diffuse large B-cell lymphoma.

|May 20, 2026
Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial.

|Jul 26, 2024
Histopathology of peritonitis due to infectious mononucleosis with background Chlamydia trachomatis infection: A case report and literature review.

Yuto Kaimi, Tomoaki Naka, Hiroshi Yoshida

|Feb 13, 2024
Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.

Yuto Kaimi, Yuka Takahashi, Hirokazu Taniguchi

|May 17, 2022
Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies.

Suguru Fukuhara, Yuji Oshikawa-Kumade, Yasunori Kogure

|Aug 02, 2021
Diagnostic utility and prognostic significance of the Ki-67 labeling index in diffuse large B-cell lymphoma transformed from follicular lymphoma: a study of 76 patients.

Akiko Miyagi Maeshima, Hirokazu Taniguchi, Yoshikazu Hori

Pageof 3

Frequent Collaborators

4 joint publications

Shinichi Makita

3 joint publications

Dai Maruyama

3 joint publications

Hiromichi Matsushita

2 joint publications

Junji Koya